Sustained release of heparin from polymeric particles for inhibition of human vascular smooth muscle cell proliferation.
Vascular smooth muscle cell (SMC) growth plays an important role in atherosclerosis, restenosis and venous bypass graft disease. With systemic drug administration no effective therapy for restenosis and venous bypass graft disease is available. This could be due to low local concentrations of the drugs at the target site. A directed delivery of drugs to tissues with a sustained release system during percutaneous transluminal coronary angioplasty (PTCA) or during bypass surgery could provide high concentrations of drugs at the target site and avoid systemic side effects. In the present study heparin was encapsulated by spray-drying into biodegradable poly(D, L-lactic-co-glycolic acid) (PLGA) to obtain a system for prolonged drug release. SMC were cultured from saphenous vein explants obtained from patients undergoing coronary bypass surgery. Cell proliferation was measured by [(3)H]thymidine incorporation. Heparin release from PLGA 50:50 microspheres in an isoosmolar PBS buffer (pH=7.4) showed a triphasic profile with an initial burst (completed after 24 h), a dormant period and a final stage with increased release rate, which lasted about 10-14 days. Cell proliferation as measured by [(3)H]thymidine incorporation was markedly stimulated by platelet-derived growth factor-BB (PDGF-BB) (5 ng/ml) or serum (5%). Proliferation of SMC was equally reduced (50%; P<0.05; n=9-11) by native heparin or heparin released from PLGA microspheres, while PLGA microspheres without heparin loading had no effect on [(3)H]thymidine incorporation in human SMC. Similar results were also obtained when SMC were stimulated with 5% serum instead of PDGF-BB (50%; P<0.05; n=6). Thus, heparin encapsulated into PLGA microspheres was released over a prolonged period of time and thereby effectively reduced human SMC proliferation stimulated either with PDGF or serum. Biodegradable PLGA microspheres may also be used to encapsulate other antiproliferative agents and provide a new approach for local drug delivery after PTCA. This may help to prevent restenosis after PTCA or to reduce graft disease after coronary bypass graft surgery.
Yang
Z
Z
Cardiovascular Research, Institute of Physiology, University Zürich-Irchel, 8057, Zürich, Switzerland.
Birkenhauer
P
P
Julmy
F
F
Chickering
D
D
Ranieri
J P
JP
Merkle
H P
HP
Lüscher
T F
TF
Gander
B
B
D000925:Anticoagulants / Q000494:pharmacology; D000077214:Becaplermin; D001672:Biocompatible Materials / Q000737:chemistry; D002455:Cell Division / Q000187:drug effects*; D002478:Cells, Cultured; D003692:Delayed-Action Preparations / Q000493:pharmacokinetics*; D004357:Drug Synergism; D006493:Heparin / Q000493:pharmacokinetics*; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry; D008297:Male; D008855:Microscopy, Electron, Scanning; D008863:Microspheres; D008875:Middle Aged; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism*; D010316:Particle Size; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D011100:Polyglycolic Acid / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry; D020574:Proto-Oncogene Proteins c-sis; D012501:Saphenous Vein / Q000187:drug effects; D013936:Thymidine / Q000378:metabolism
D000925:Anticoagulants; D001672:Biocompatible Materials; D003692:Delayed-Action Preparations; D010982:Platelet-Derived Growth Factor; D011108:Polymers; D020574:Proto-Oncogene Proteins c-sis; D000077214:Becaplermin; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D006493:Heparin; D013936:Thymidine